Royalty Pharma Announces Transformative Step in Company’s Evolution With Acquisition of its External Manager and $3 Billion Share Repurchase Program

NEW YORK, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced two major steps to enhance shareholder value.

Henry Fernandez, lead independent director of Royalty Pharma’s Board of Directors and Chairman and Chief Executive Officer of MSCI Inc., said, “The Board of Directors of Royalty Pharma is pleased to announce this transaction which it believes increases shareholder alignment and enhances corporate governance. Coupled with the new $3 billion share repurchase authorization, we expect these actions to drive shareholder value creation over the long-term.”

Read more at globenewswire.com